Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study

Raffaele de Caterina (1) , Peter Kelly (2, 3, 4) , Pedro Monteiro , Jean Claude Deharo (5) , Carlo de Asmundis , Esteban López-De-Sá , Thomas W. Weiss , Johannes Waltenberger , Jan Steffel , Joris R. de Groot , Pierre Lévy (6, 7) , Ameet Bakhai , Wolfgang Zierhut (8) , Petra Laeis (9) , Paul-Egbert Reimitz , Paulus Kirchhof

1 Institute of Clinical Physiology
2 NS Research
3 Division of Medicine
4 Neurovascular Clinical Science Unit, Catherine McAuley Centre
5 Département de Cardiologie [Hôpital de la Timone - APHM]
6 LEDa - Laboratoire d'Economie de Dauphine
7 Legos - Laboratoire d'Economie et de Gestion des Organisations de Santé
8 DEPARTMENT OF MEDICINE, ROYAL FREE - Department of Medicine, Royal Free
9 Daiichi Sankyo Inc.

Mots clés: Prospective Studies; Europe; epidemiology; Treatment Outcome; ETNA-AF-Europe study; PREFER in AF

Domaines: Économie et finance quantitative [q-fin]

Raffaele de Caterina, Peter Kelly, Pedro Monteiro, Jean Claude Deharo, Carlo de Asmundis, et al.. Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study. Journal of Cardiovascular Medicine, 2019, 20 (2), ⟨10.2459/JCM.0000000000000737⟩. ⟨hal-02273969⟩